Report Highlights
The global market for viral vector and plasmid DNA technologies is expected to grow from $2.9 billion in 2023 to $7.1 billion by the end of 2028, at a compound annual growth rate (CAGR) of 19.7% from 2023 through 2028.
Report Includes
- 93 data tables and 47 additional tables
- An overview of the global market for viral vector and plasmid DNA
- Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market size and revenue growth prospects for viral vector and plasmid DNA, along with a market share analysis by product type, application and geographic region
- A look at the innovations, technological advances, and product launches from leading companies
- Analysis of the industry’s regulatory framework and policies, and its product pipeline
- Discussion of ESG challenges and ESG practices
- Analysis of the key companies’ market shares, proprietary technologies, strategic alliances and other market strategies, and patents
- Profiles of the leading players in the industry
Report Scope
The report provides a comprehensive summary of the viral vector and plasmid DNA technologies market focusing cell and gene therapies, along with detailed competitive landscape and profiles of key market players that include revenue, product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges, and opportunities. This research study discusses historical, current, and potential market size. The report will enable market players and new entrants to make informed decisions about the production and licensing of goods and services. Organizations, distributors, and exporters should find the information about market development and trends useful. The study segments the market on the basis of product type, applications, and end use. Geographical market analysis is provided for all the major segments. The report offers country-level analysis of markets to provide a better understanding of the major segments.
The market is divided into segments and by application/industry as follows:
By product type:
- Viral vector.
- Plasmid DNA.
By application:
- Cancer.
- Genetic disorders.
- Infectious diseases.
- Cardiovascular diseases.
- Other diseases.
By end-user:
- Research institutes.
- Pharmaceutical and biopharmaceutical companies.
Each area is covered in detail, identifying current products in the market in the base year (2022), measuring the current market size and identifying current and potential market drivers, forecasting for 2028, assessing current and potential competitors, and identifying current competitor market shares for 2022.
Report Synopsis
Report Metrics | Details | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Base year considered | 2022 | ||||||||||||||
Forecast period considered | 2023-2028 | ||||||||||||||
Base year market size | $2.4 billion | ||||||||||||||
Market size forecast | $7.1 billion | ||||||||||||||
Growth rate | CAGR of 19.7% from 2023 to 2028 | ||||||||||||||
Units considered | $ Millions | ||||||||||||||
Segments covered | By Product Type, Application, End User, and Region | ||||||||||||||
Regions covered | North America, Europe, Asia-Pacific, Latin America, and the Rest of the World (RoW) | ||||||||||||||
Key Market Drivers |
|
||||||||||||||
Companies studied |
|
Frequently Asked Questions (FAQs)
What are the key factors driving the growth of the viral vector and plasmid DNA technologies market?
Analyst Credentials
Gundreddy Gopinadh– Associate Consultant-Life Sciences Research
Gopinadh is an experienced professional with nearly nine years in the market research industry and experience in research and analysis, specializing in medical devices, pharmaceuticals, biotechnology, and in-vitro diagnostics verticals. He is an expert in handling custom projects by gathering data points, analyzing market trends, and ultimately providing clients with accurate market size numbers, actionable insights, and recommendations based on their unique business needs. Academically, Gopinadh holds a master’s degree in biotechnology from VIT University.
Report Highlights
The global viral vector and plasmid DNA technologies market should grow from $500 million in 2019 to over $1.1 billion by 2024 with a compound annual growth rate (CAGR) of 18.0% during the period, 2019-2024.
Report Includes
- 44 data tables and 14 additional tables
- An in-depth assessment of the global viral vector and plasmid DNA technologies market within the life sciences sectors
- Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
- The latest information on key technical advances in different viral vector and plasmid DNA technologies, and the extent of adoption by commercial customers and regulatory authorities
- A proprietary analysis of the market including an easy-to-understand graphical representation of facts, innovations in pharmaceutical and biotechnology companies, and R&D activities in viral vector-based treatments and Plasmid DNA vaccines
- Key strategies adopted by major players in the market and the impact of new technological developments in developed and emerging markets
- Assessment of the suppliers’ landscape on the basis of companies best positioned to meet this ever evolving demand
- Comprehensive company profiles of market leading players, including Aldevron LLC, Merck KGaA, Lonza Group Ltd., GenScript Biotech Corp., Pfizer Inc., and Thermo Fisher Scientific, Inc.
Related Reports
Synthetic Biology: Global Markets
The global market for synthetic biology products was valued at $15.4 billion in 2023. The market is projected to grow from $19.3 billion in 2024 to $61.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 26.1% from 2024 through 2029.
Global Market for Cell and Gene Therapy
The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028.
mRNA: Therapeutics and Global Markets
The global market for mRNA therapeutics is expected to decline from $33 billion in 2023 to $21 billion by the end of 2028, at a compound annual growth rate (CAGR) of -8.6% during the forecast period of 2023-2028.
Cell and Gene Therapy Manufacturing Services Market
The global cell and gene therapy manufacturing services market reached $4.9 billion in 2022, should reach $5.7 billion by 2023 and $11.8 billion by 2028 with a compound annual growth rate (CAGR) of 15.7% during the forecast period of 2023-2028.
Recent Reports
Artificial Intelligence (AI) in Cancer
The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Induced Pluripotent Stem Cells: Global Markets
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.
Commercial Amino Acids
The global market for commercial amino acids was valued at $30.1 billion in 2023. It is expected to grow from $31.8 billion in 2024 to $42.8 billion by 2029, at a compound annual growth rate (CAGR) of 6.1% from 2024 through 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More